Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase VII results from ECHO-202/KEYNOTE-037.

被引：35
|
作者：
Hamid, Omid
Bauer, Todd Michael
Spira, Alexander I.
Olszanski, Anthony J.
Patel, Sandip Pravin
Wasser, Jeffrey S.
Smith, David C.
Balmanoukian, Ani Sarkis
Aggarwal, Charu
Schmidt, Emmett V.
Zhao, Yufan
Gowda, Hema
Gangadhar, Tara C.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.6010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6010
引用
收藏
页数：6
相关论文
共 50 条
  • [21] The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)
    Toshihiko Doi
    Yutaka Fujiwara
    Kohei Shitara
    Toshio Shimizu
    Kan Yonemori
    Nobuaki Matsubara
    Izumi Ohno
    Takahiro Kogawa
    Yoichi Naito
    Lance Leopold
    Mihaela Munteanu
    Naoyoshi Yatsuzuka
    Shi Rong Han
    Ayman Samkari
    Noboru Yamamoto
    Investigational New Drugs, 2021, 39 : 152 - 162
  • [22] Phase 3 study of epacadostat plus pembrolizumab with or without platinumbased chemotherapy vs pembrolizumab plus chemotherapy for first-line metastatic non-small cell lung cancer (mNSCLC): ECHO-306/KEYNOTE-715
    Garassino, M.
    Rubin, S.
    Zhao, Y.
    Luo, Y.
    Samkari, A.
    Hui, R.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S115 - S115
  • [23] Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.
    Balar, Arjun Vasant
    Plimack, Elizabeth R.
    Grivas, Petros
    Necchi, Andrea
    De Santis, Maria
    Pang, Lei
    Keefe, Stephen Michael
    O'Hayer, Kevin
    Zhao, Yufan
    De Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort
    Seiwert, Tanguy Y.
    Haddad, Robert I.
    Gupta, Shilpa
    Mehra, Ranee
    Tahara, Makoto
    Berger, Raanan
    Lee, Se-Hoon
    Burtness, Barbara
    Le, Dung T.
    Heath, Karl
    Blum, Amy
    Dolled-Filhart, Marisa
    Emancipator, Kenneth
    Pathiraja, Kumudu
    Cheng, Jonathan D.
    Chow, Laura Q.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
  • [25] Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.
    Seiwert, Tanguy Y.
    Haddad, Robert I.
    Gupta, Shilpa
    Mehra, Ranee
    Tahara, Makoto
    Berger, Raanan
    Lee, Se-Hoon
    Burtness, Barbara
    Le, Dung T.
    Heath, Karl
    Blum, Amy
    Dolled-Filhart, Marisa
    Emancipator, Kenneth
    Pathiraja, Kumudu
    Cheng, Jonathan D.
    Chow, Laura Q.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study.
    Ott, Patrick Alexander
    Bang, Yung-Jue
    Berton-Rigaud, Dominique
    Elez, Elena
    Pishvaian, Michael J.
    Rugo, Hope S.
    Puzanov, Igor
    Morgan, Mark Aloysuis
    Mehnert, Janice M.
    Aung, Kyaw Lwin
    Carrigan, Marion
    Saraf, Sanatan
    Chen, Mei
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.
    Frenel, Jean-Sebastien
    Le Tourneau, Christophe
    O'Neil, Bert H.
    Ott, Patrick Alexander
    Piha-Paul, Sarina Anne
    Gomez-Roca, Carlos Alberto
    Van Brummelen, Emilie
    Rugo, Hope S.
    Thomas, Shari
    Saraf, Sanatan
    Chen, Mei
    Varga, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
    Im, Seock-Ah
    Cortes, Javier
    Cescon, David W.
    Yusof, Mastura Md
    Iwata, Hiroji
    Masuda, Norikazu
    Takano, Toshimi
    Huang, Chiun-Sheng
    Chung, Chi-Feng
    Tsugawa, Koichiro
    Park, Yeon Hee
    Matsumoto, Koji
    Inoue, Kenichi
    Kwong, Ava
    Loi, Sherene
    Fu, Wei
    Pan, Wilbur
    Karantza, Vassiliki
    Rugo, Hope S.
    Schmid, Peter
    NPJ BREAST CANCER, 2024, 10 (01)
  • [29] Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775
    Yonemori, Kan
    Yunokawa, Mayu
    Ushijima, Kimio
    Sakata, Jun
    Shikama, Ayumi
    Minobe, Shinichiro
    Usami, Tomoka
    Enomoto, Takayuki
    Takehara, Kazuhiro
    Hasegawa, Kosei
    Yamagami, Wataru
    Yamamoto, Keiko
    Han, Shirong
    Dutta, Lea
    Orlowski, Robert
    Miura, Takuma
    Makker, Vicky
    Fujiwara, Keiichi
    CANCER SCIENCE, 2022, 113 (10) : 3489 - 3497
  • [30] INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)
    Fujiwara, Yutaka
    Shitara, Kohei
    Shimizu, Toshio
    Yonemori, Kan
    Matsubara, Nobuaki
    Ohno, Izumi
    Kogawa, Takahiro
    Naito, Yoichi
    Leopold, Lance
    Sasahara, Kahori
    Yatsuzuka, Naoyoshi
    Takami, Tomoko
    Shimamoto, Takashi
    Yamamoto, Noboru
    Doi, Toshihiko
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345